B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line

IUBMB Life

Volumn 64, Issue 11, 2012, Pages 889-900

  Zhou, Huimin ^a   Zhang, Zhaohai ^a   Liu, Chunqing ^a   Jin, Changgong ^a   Zhang, Jianing ^a   Miao, Xiaoyan ^a   Jia, Li ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

B4GALT1; glycogene; hedgehog; human leukemia cell line; multidrug resistance

Indexed keywords

1,4 N ACETYLGALACTOSAMINE; ANTINEOPLASTIC AGENT; BETA 1,4 GALACTOSYLTRANSFERASE 1; DOXORUBICIN; GALACTOSYLTRANSFERASE; GLYCOPROTEIN; N ACETYLGALACTOSAMINE; PACLITAXEL; RNA; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL MEMBRANE; CELL PROLIFERATION; CELL STRUCTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GALACTOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, NUDE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84867796359     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1080     Document Type: Article

References (43)

1. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., and, Gottesman, M. M., (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234.
2. Honma, K., Iwao-Koizumi, K., Takeshita, F., Yamamoto, Y., Yoshida, T., et al. (2008) RPN2 gene confers docetaxel resistance in breast cancer. Nat. Med. 14, 939-948.
3. Kudo, T., Nakagawa, H., Takahashi, M., Hamaguchi, J., Kamiyama, N., et al. (2007) N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol. Cancer. 6, 32-40.
4. Nakano, M., Saldanha, R., Göbel, A., Kavallaris, M., and, Packer, N. H., (2011) Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. Mol. Cell Proteomics. 10, M111.009001.
5. Lairson, L. L., Henrissat, B., Davies, G. J., and, Withers, S. G., (2008) Glycosyltransferases: structures, functions, and mechanisms. Annu. Rev. Biochem. 77, 521-555.
6. Spiro, R. G., (2002) Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12, 43R-56R.
7. Haltiwanger, R. S., and, Lowe, J. B., (2004) Role of glycosylation in development. Annu. Rev. Biochem. 73, 491-537.
8. Malagolini, N., Chiricolo, M., Marini, M., and, Dall'Olio, F., (2009) Exposure of alpha2,6-sialylated lactosaminic chains marks apoptotic and necrotic death in different cell types. Glycobiology 19, 172-181.
9. Amado, M., Almeida, R., Schwientek, T., and, Clausen, H., (1999) Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions. Biochim. Biophys. Acta 1473, 35-53.
10. Ramakrishnan, B., Boeggeman, E., Ramasamy, V., and, Qasba, P. K., (2004) Structure and catalytic cycle of beta-1,4-galactosyltransferase. Curr. Opin. Struct. Biol. 14, 593-600.
11. Qian, J., Cheng, C., Liu, H., Chen, J., Yan, M., et al. (2007) Expression of beta-1,4-galactosyltransferase-I in rat during inflammation. Inflammation 30, 59-68.
12. Shen, A., Qian, J., Liu, L., Liu, H., Chen, J., et al. (2008) The role of beta-1,4-galactosyltransferase-I in the skin wound-healing process. Am. J. Dermatopathol. 30, 10-15.
13. Hansske, B., Thiel, C., Lubke, T., Hasilik, M., Honing, S., et al. (2002) Deficiency of UDP-galactose:N-acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type IId. J. Clin. Invest. 109, 725-733.
14. Johnson, F. M., and, Shur, B. D., (1999) The level of cell surface beta1,4-galactosyltransferase I influences the invasive potential of murine melanoma cells. J. Cell Sci. 112, 2785-2795.
15. Zhu, X., Jiang, J., Shen, H., Wang, H., Zong, H., et al. (2005) Elevated beta1,4-galactosyltransferase I in highly metastatic human lung cancer cells. Identification of E1AF as important transcription activator. J. Biol. Chem. 280, 12503-12516.
16. Yamashita, H., Kubushiro, K., Ma, J., Fujii, T., Tsukazaki, K., et al. (2003) Alteration in the metastatic potential of ovarian cancer cells by transfection of the antisense gene of beta-1,4-galactosyltransferase. Oncol. Rep. 10, 1857-1862.
17. Wei, Y., Liu, D., Zhou, F., Ge, Y., Xu, J., et al. (2008) Identification of beta-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell. J. Hepatol. 49, 1029-1037.
18. Nüsslein-Volhard, C., and, Wieschaus, E., (1980) Mutations affecting segment number and polarity in Drosophila. Nature 287, 795-801.
19. Mullor, J. L., Sanchez, P., and, Altaba, A., (2002) Pathways and consequences: hedgehog signalling in human disease. Trends Cell Biol. 12, 562-569.
20. Pignot, G., Vieillefond, A., Vacher, S., Zerbib, M., Debre, B., et al. (2012) Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br. J. Cancer 106, 1177-1186.
21. Cui, W., Wang, L. H., Wen, Y. Y., Song, M., Li, B. L., et al. (2010) Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Sci. 101, 927-933.
22. Kim, J. E., Singh, R. R., Cho-Vega, J. H., Drakos, E., Davuluri, Y., et al. (2009) Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod. Pathol. 22, 1312-1320.
23. Yang, L., Su, X., and, Xie, J., (2012) Activation of hedgehog pathway in gastrointestinal cancers. Vitam. Horm. 88, 461-472.
24. Queiroz, K. C., Ruela-de-Sousa, R. R., Fuhler, G. M., Aberson, H. L., Ferreira, C. V., et al. (2010) Hedgehog signaling maintains chemoresistance in myeloid leukemia cells. Oncogene 29, 6314-6322.
25. Kobune, M., Takimoto, R., Murase, K., Iyama, S., Sato, T., et al. (2009) Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemia cells. Cancer Sci. 100, 948-955.
26. Yeung, J., Esposito, M. T., Gandillet, A., Zeisig, B. B., Griessinger, E., et al. (2010) β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 18, 606-618.
27. Schreck, K. C., Taylor, P., Marchionni, L., Gopalakrishnan, V., Bar, E. E., et al. (2010) The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin. Cancer Res. 16, 6060-6070.
28. Styczynski, J., and, Drewa, T., (2007) Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochim. Pol. 54, 717-726.
29. An, H. J., Kronewitter, S. R., de Leoz, M. L., and, Lebrilla, C. B., (2009) Glycomics and disease markers. Curr. Opin. Chem. Biol. 13, 601-607.
30. Arnold, J. N., Saldova, R., Hamid, U. M., and, Rudd, P. M., (2008) Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8, 3284-3293.
31. Itakura, Y., Nakamura-Tsuruta, S., Kominami, J., Sharon, N., Kasai, K., et al. (2007) Systematic comparison of oligosaccharide specificity of Ricinus communis agglutinin I and Erythrina lectins: a search by frontal affinity chromatography. J. Biochem. 142, 459-469.
32. Yamaguchi, N., and, Fukuda, M. N., (1995) Golgi retention mechanism of beta-1,4-galactosyltransferase. Membrane-spanning domain-dependent homodimerization and association with alpha- and beta-tubulins. J. Biol. Chem. 270, 12170-12176.
33. Do, K. Y., Do, S. I., and, Cummings, R. D., (1997) Differential expression of LacdiNAc sequences (GalNAc beta 1-4GlcNAc-R) in glycoproteins synthesized by Chinese hamster ovary and human 293 cells. Glycobiology 7, 183-194.
34. Niu, S., Fei, M., Cheng, C., Yan, M., Gao, S., et al. (2008) Altered beta-1,4-galactosyltransferase I expression during early inflammation after spinal cord contusion injury. J. Chem. Neuroanat. 35, 245-256.
35. Alavi, A., Axford, J. S., Hay, F. C., and, Jones, M. G., (1998) Tissue-specific galactosyltransferase abnormalities in an experimental model of rheumatoid arthritis. Ann. Med. Interne (Paris). 149, 251-260.
36. Chen, J., Lu, L., Shi, S., and, Stanley, P., (2006) Expression of Notch signaling pathway genes in mouse embryos lacking beta4galactosyltransferase-1. Gene Expr. Patterns 6, 376-382.
37. Li, Z., Zong, H., Kong, X., Zhang, S., Wang, H., et al. (2006) Cell surface beta 1, 4-galactosyltransferase 1 promotes apoptosis by inhibiting epidermal growth factor receptor pathway. Mol. Cell Biochem. 291, 69-76.
38. Yang, H., Yuan, Q., Chen, Q., Li, C., Wu, X., et al. (2011) β-1,4-Galactosyltransferase I promotes tumor necrosis factor-α autocrine via the activation of MAP kinase signal pathways in Schwann cells. J. Mol. Neurosci. 45, 269-276.
39. Hathaway, H. J., and, Shur, B. D., (1996) Mammary gland morphogenesis is inhibited in transgenic mice that overexpress cell surface beta1, 4-galactosyltransferase. Development 122, 2859-2872.
40. Shi, X., Amindari, S., Paruchuru, K., Skalla, D., Burkin, H., et al. (2001) Cell surface beta-1,4-galactosyltransferase-I activates G protein-dependent exocytotic signaling. Development 128, 645-654.
41. Metcalfe, C., and, de Sauvage, F. J., (2011) Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Res. 71, 5057-5061.
42. Tao, H., Jin, Q., Koo, D. I., Liao, X., Englund, N. P., et al. (2011) Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened. Chem. Biol. 18, 432-437.
43. Cui, D., Xu, Q., Wang, K., and, Che, X., (2010) Gli1 is a potential target for alleviating multidrug resistance of gliomas. J. Neurol. Sci. 288, 156-166.